Drugs / 18F-JK-PSMA-7
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05622162 | Dec 2022 → Jun 2024 | prostate cancer | ITEL Telecomunicazioni Srl | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-JK-PSMA-7 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05622162 ↗ |
| Modality | Diagnostic / imaging agent | “The investigational product 18F-JK-PSMA-7 is a diagnostic radiopharmaceutical for use with positron emission tomography (PET).” NCT05622162 ↗ |
| Route | Intravenous | “18F-JK-PSMA-7 is administered as direct intravenous injection.” NCT05622162 ↗ |